Cem Açık, Country President of Pfizer Turkey, Appointed to Global Role

Pfizer Turkey Country President Cem Açık Appointed to Global Role Mustafa Cem Açık, who joined Pfizer Turkey 17 years ago and has served as Pfizer Turkey Country President since 2019, has been appointed globally as Vice President, Internal Specialties & Vaccines Emerging Markets Group Leader. A graduate of Tarsus American College and Boğaziçi University Industrial Engineering program, M. Cem Açık completed his MBA at Carnegie Mellon University in the United States. [caption id="attachment_151352" align="aligncenter"] Cem Açık[/caption] Since joining Pfizer in 2005, Açık has held various positions of significant responsibility, ranging from marketing and sales to strategy, business unit general management, and regional management. He has served as Pfizer Turkey Country President since 2019. Before joining Pfizer, Açık worked as a team leader at McKinsey & Company's Dallas and Istanbul offices, serving the energy, retail, FMCG and pharmaceutical sectors. M. Cem Açık commented on his appointment: "Pfizer is a biotechnology company with the status of a 'leadership school,' operating with the principle that science will prevail, supporting flexible work and creating major opportunities for employees to develop themselves. Working at Pfizer for many years enables you to grow as a competent leader who will make a difference in every area. The rotation culture at Pfizer Turkey has greatly contributed to my taking on increasingly greater responsibilities throughout my career. I am proud to assume such an important and valued global position under the Pfizer umbrella following my time in Turkey."   About Pfizer For 170 years, Pfizer has worked toward the goal of "pioneering breakthrough innovations that change patients' lives," focusing on new treatments with innovative and high-tech approaches in today's pharmaceutical industry. While Pfizer produces the world's most widely used essential health products and contributes to health protection through medicines and vaccines, it also conducts research on treatments that will shape the future and provide patients with maximum benefit. At Pfizer, treatments are being developed against universal health challenges such as cancer and cardiovascular diseases, while efforts continue to combat rare diseases. Pfizer contributes to the business, investment and innovation environment through collaborative work with universities, associations and the public. The company has served Turkey since 1957.